Paul Hampel
@hampel_p
Hematologist @MayoClinic specializing in CLL and Lymphoma. Tweets are my own.
Great coverage all #ASH23 @JoselleCookMD and @nadineabdal !
Our “Best of” #CLL and #Lymphoma picks for #ASH23 …with a spin! 👑#ASHNewsDaily ashpublications.org/ashnewsdaily/n… @MazieTsangMD @CaThompsonMD @GitaThanaMD @hampel_p @UDuraniMD @hjcherng @JaneWinterMD
Best of Lugano at Lake Tahoe this October - ABSTRACT SUBMISSIONS OPEN (deadline July 18) ce.mayo.edu/content/lympho…. Early Career Investigators and Trainees interested in Lymphoma/CLL - check this out! #ICML18 #lymsm
Continue the #18ICML lakeside conversation at “Best of Lugano 2025”, an international collaboration between Mayo Clinic and ICML in Lake Tahoe, CA Oct 9-11! Dr. Patrick Johnston will be chairing our CNS lymphoma discussion. ce.mayo.edu/hematology-and…
Looking forward to discussing Richter transformation tonight on National Lymphoma Rounds! lymphoma.org/nationalrounds/ @lymphoma @GitaThanaMD
Looking forward to speaking @ Current Perspectives on the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) this afternoon (TODAY!) with @CancerCare & @CllSociety! Joined also by Drs @ChristineRyanMD and Christopher Jensen!
Massive data set in the Richter setting with timely insights. Important collaborative work - well done, @AdamKittai!
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL | Blood Cancer Journal rdcu.be/eaHne
New insights in CLL/SLL management with @hampel_p (@MayoClinic) ⭐Hodgkin lymphoma transformation outcomes in chemo-naïve CLL/SLL patients in the modern therapy era ⭐Venetoclax efficacy in cBTKi-treated, chemo-naïve CLL patients #ASH24 #CLL #HodgkinLymphoma #Lymphoma #Leusm…
We are seeking a lymphoma investigator to join our Lymphoid Malignancies Disease Group at @MayoClinic in Rochester, MN. Join @GregNowakowski, Steve Ansell, @WitzigLab and may other talented individuals to advance lymphoma care and research. jobs.mayoclinic.org/job/rochester/…
Fantastic work from @kenderian_ss lab!
A Mayo Clinic team showed in Nat Commun that IL4 mAb improves antitumor efficacy and reduces CART cell exhaustion in an MCL xenograft model. The strategy should be clinically translatable as many IL4 targeting therapies are in clinical development. tinyurl.com/IL4strat
What an incredible feeling to present my first #ASCO24 talk ever! Grateful for the opportunity! Hem malignancy highlights from Day 1: @UWCarbone @uw_hemeoncpc @uw_medicine @WomenInLymphoma
Inspiring talk @sparikhmd to conclude an inspiring #GCLLSG2024! Thank you for the hospitality throughout the meeting @HallekMichael and #GCLLSG!
A Mayo Clinic team showed in Nat Commun that IL4 mAb improves antitumor efficacy and reduces CART cell exhaustion in an MCL xenograft model. The strategy should be clinically translatable as many IL4 targeting therapies are in clinical development. tinyurl.com/IL4strat
Important FDA approval of Liso-Cel in CLL. Excited for a new therapy for our patient @MayoCancerCare @MayoClinic
Unpacking the Significance of Liso-Cel’s @US_FDA Approval and Continued Investigation in CLL/SLL @kenderian_ss @MayoClinic #leusm onclive.com/view/unpacking…
Great work leading this large effort @Adam! Novel treatment strategies needed for patients with RT and any prior CLL therapy.
Oral presentation for RT #ASH23! Internat collab of RT that develops on SMI only, no CIT. This is RT that will develop in what is now standard of care for #CLL. N = 242 Time CLL to RT 47mos 54% BTKi, 5% BCL2i, 27% both Med OS of 8.2 mo after SMI TRMT for CLL assoc w/ worse OS
Interested in CLL? Consider a job at @MayoCancerCare! The CLL group is phenomenal and has a great spirit of camaraderie and kindness! If you’re interested in CLL, research, and thrive in a supportive and fun work environment, consider applying!
Check out our latest work on transcriptomic profiles of #CLL, drivers of MRD response and 5-year results from CLL14 – all out today in one paper @NatureComms : nature.com/articles/s4146… Key results in a brief 🧵
Celebrating the milestone birthdays of two international treasures in lymphoma! Happy birthday Toms (Witzig and Habermann)! And yes, those are “rituximab” cupcakes @MayoCancerCare #MayoLymphoma @GregNowakowski @CaThompsonMD @hampel_p @YucaiWangMD @YiLinMDPhD @jonaspaludo
BTKi bonanza in CLL/SLL: Sorting out the differences by @hampel_p and @sparikhmd (wiley.com) onlinelibrary.wiley.com/share/QIJGTIJ5…